Clinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs

Objectives: Concomitant food intake influences pharmacokinetics of first-line anti-tuberculosis drugs in healthy volunteers. However, in treatment-naive TB patients who are starting with drug treatment, data on the influence of food intake on the pharmacokinetics are absent. This study aimed to quantify the influence of food on the pharmacokinetics of isoniazid, rifampicin, ethambutol and pyrazinamide in TB patients starting anti-TB treatment. Methods: A prospective randomized cross-over pharmacokinetic study was conducted in treatment-naive adults with drug-susceptible TB. They received isoniazid, rifampicin and ethambutol intravenously and oral pyrazinamide on day 1, followed by oral administration of these drugs in fasted and fed condition on two consecutive days. Primary outcome was the bioavailability while fasting and with concomitant food intake. This study was registered with clinicaltrial.gov identifier NCT02121314. Results: Twenty subjects completed the study protocol. Absolute bioavailability in the fasted state and the fed state was 93% and 78% for isoniazid, 87% and 71% for rifampicin and 87% and 82% for ethambutol. Food decreased absolute bioavailability of isoniazid and rifampicin by 15% and 16%, respectively. Pyrazinamide AUC 0–24 was comparable for fasted (481 mg · h/L) and fed state (468 mg · h/L). Food lowered the maximum concentration of isoniazid, rifampicin and pyrazinamide by 42%, 22% and 10% respectively. Time to maximum concentration was delayed for isoniazid, rifampicin and pyrazinamide. The pharmacokinetics of ethambutol were unaffected by food.

[1]  B. Greijdanus,et al.  Quantification of isoniazid, pyrazinamide and ethambutol in serum using liquid chromatography-tandem mass spectrometry , 2015 .

[2]  J. Kosterink,et al.  Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis , 2015, Antimicrobial Agents and Chemotherapy.

[3]  John L. Johnson,et al.  Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. , 2015, American journal of respiratory and critical care medicine.

[4]  J. Bigna,et al.  Factors Associated with Death during Tuberculosis Treatment of Patients Co-Infected with HIV at the Yaoundé Central Hospital, Cameroon: An 8-Year Hospital-Based Retrospective Cohort Study (2006–2013) , 2014, PloS one.

[5]  A. Crook,et al.  Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. , 2014, The New England journal of medicine.

[6]  P. Butcher,et al.  High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. , 2014, The New England journal of medicine.

[7]  P. V. van Helden,et al.  Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.

[8]  A. Donders,et al.  Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. , 2014, International journal of antimicrobial agents.

[9]  K. Bai,et al.  Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients. , 2014, Journal of the Formosan Medical Association = Taiwan yi zhi.

[10]  H. McIlleron,et al.  Serum drug concentrations predictive of pulmonary tuberculosis outcomes. , 2013, The Journal of infectious diseases.

[11]  B. Greijdanus,et al.  Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  I. Kawase,et al.  NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy , 2012, European Journal of Clinical Pharmacology.

[13]  Akash Khandelwal,et al.  A Semimechanistic Pharmacokinetic-Enzyme Turnover Model for Rifampin Autoinduction in Adult Tuberculosis Patients , 2012, Antimicrobial Agents and Chemotherapy.

[14]  J. Pasipanodya,et al.  Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. , 2011, The Journal of infectious diseases.

[15]  J. Alffenaar,et al.  Dried blood spots: a new tool for tuberculosis treatment optimization. , 2011, Current pharmaceutical design.

[16]  Siv Jönsson,et al.  Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients , 2011, Antimicrobial Agents and Chemotherapy.

[17]  J. Morais,et al.  The new European Medicines Agency guideline on the investigation of bioequivalence. , 2010, Basic & clinical pharmacology & toxicology.

[18]  T. Gumbo New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability , 2010, Antimicrobial Agents and Chemotherapy.

[19]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: rifampicin. , 2009, Journal of pharmaceutical sciences.

[20]  B. Greijdanus,et al.  Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[21]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochloride. , 2008, Journal of pharmaceutical sciences.

[22]  B. Alisjahbana,et al.  Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis Patients , 2007, Antimicrobial Agents and Chemotherapy.

[23]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: isoniazid. , 2007, Journal of pharmaceutical sciences.

[24]  R. Jelliffe,et al.  Pharmacokinetics of ethambutol in children and adults with tuberculosis. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[25]  C. Nishida,et al.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies , 2004, The Lancet.

[26]  C. Doré,et al.  Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. , 2003, American journal of respiratory and critical care medicine.

[27]  Charles L Daley,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[28]  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis , 2002 .

[29]  R. Namdar,et al.  Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[30]  R. Jelliffe,et al.  Pharmacokinetics of Ethambutol under Fasting Conditions, with Food, and with Antacids , 1999, Antimicrobial Agents and Chemotherapy.

[31]  R. Jelliffe,et al.  Pharmacokinetics of Pyrazinamide under Fasting Conditions, with Food, and with Antacids , 1998, Pharmacotherapy.

[32]  C. Moshiro,et al.  Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[33]  A. R. Frisancho Physical Status: The Use and Interpretation of Anthropometry , 1996, The American Journal of Clinical Nutrition.

[34]  C. Zent,et al.  Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. , 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[35]  N G Norgan,et al.  Population differences in body composition in relation to the body mass index. , 1994, European journal of clinical nutrition.

[36]  M. Holdiness,et al.  Clinical Pharmacokinetics of the Antituberculosis Drugs , 1984, Clinical pharmacokinetics.

[37]  K. Krishnaswamy,et al.  Rifampicin kinetics in undernutrition. , 1984, British journal of clinical pharmacology.

[38]  B. Culliton HEALTH , 1979, Science.

[39]  K. Krishnaswamy Drug Metabolism and Pharmacokinetics in Malnutrition , 1978 .

[40]  D. Burley,et al.  Effect of meals on rifampicin absorption. , 1974, Lancet.

[41]  THE WORLD HEALTH ORGANIZATION , 1954 .

[42]  B. D. de Jong,et al.  A four-month gatifloxacin-containing regimen for treating tuberculosis. , 2015, The New England journal of medicine.

[43]  G. Borm,et al.  Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. , 2013, The Lancet. Infectious diseases.

[44]  S.‐J. Lin,et al.  Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[45]  R. Namdar,et al.  Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. , 1999, Chest.